Sanofi signs landmark agreement to combat antimicrobial resistance

Sanofi signs landmark agreement to combat antimicrobial resistance
SHARE
Facebook
Linkedin

Sanofi has joined leading pharmaceutical companies from around the world to sign a roadmap to help combat the rising threat of antimicrobial resistance. This initiative is supported by the United Nations, whose General Assembly had summoned a high-level meeting on antimicrobial resistance on 21 September 2016.

The roadmap – which lays out four key commitments to be delivered by 2020 – marks an unprecedented collaboration between 13 different pharmaceutical companies. It is hoped more companies will continue to sign up.

The commitments are based on the principles identified in an industry declaration signed by 85 companies and 11 industry associations at the 2016 World Economic Forum in Davos.

 

The roadmap reflects the pharmaceutical sector’s determination to address one of the major challenges affecting health care provision worldwide.

Antimicrobial resistance occurs when bacteria and other microbes develop resistance to the drugs used to treat infections. The problem affects antimicrobials such as antibiotics, which act only on bacteria, as well as antivirals, antiparasitics and antifungals.

An independent review in 2014 found that antimicrobial resistance could lead to the deaths of as many as 10 million people every year by 2050.

The roadmap outlines four major commitments to address the problem.

 

Reducing environmental impact

 

Companies will work to reduce the environmental impact from the production of antibiotics. Company manufacturing and supply chains will be reviewed and a framework will be set up for assessing and managing antibiotic discharge.

 

Targeted use and education

 

Marketing activities, along with patient and healthcare sector education, will be reviewed to ensure only patients who need them will be prescribed antibiotics. There will also be a focus on the sharing of data between public health bodies, healthcare professionals and pharmaceutical companies to help reduce the uncontrolled purchase of antibiotics.

 

Access to new antibiotics and vaccines

 

Companies will work to improve access to current and future antibiotics, vaccines and diagnostics to help strengthen global health systems and reduce bottlenecks. New business models will be developed to balance demand for medications with appropriate antibiotic use and vaccination programs. There will also be efforts to reduce the prevalence of substandard and counterfeit antibiotics on global markets.

 

More collaboration

 

In recognition of the value new antibiotics, vaccines and diagnostics bring to society, open collaborations between industry and the public sector will also be explored.

 

Sanofi’s commitment

 

Sanofi is a world leader in research into antimicrobial resistance. The company already has a major collaboration with in Germany to identify and accelerate the development of antibiotics for infectious diseases. It also works alongside the French Ministry of Health on a number of fronts relating to antimicrobial resistance.

 

Collaborating on the roadmap is a natural ‘next step’ in Sanofi’s ongoing commitment to reducing the impact of antimicrobial resistance worldwide.

Recommended by Sanofi Le Hub

05.17.17 By Sanofi Le Hub

A guide to rheumatoid arthritis
Choose the topics that interest you, like:
or